Published on
Spark Therapeutics, Inc. recently announced a public offering issuing two-million primary shares at $47.00 per share. Included in the sale as a secondary offering are one-million shares, at $47.00, held by CHOP.
Published on
The Children’s Hospital of Philadelphia has chosen Douglas G. Hock as its new executive vice president and chief operating officer, beginning on Feb. 1.
Published on
A $1.5 million grant to CHOP from Alex’s Lemonade Stand Foundation supports an innovative treatment for children with high-risk neuroblastoma.
Published on
CHOP-based research center connects academia and auto industry to keep children safe in traffic and elsewhere.
Published on
CHOP’s Dr. John Maris comments on a just-published major study of genes that raise a child’s risk for cancer, and what this means for counseling families and patients.
Published on
New on-site milk bank will enhance process of providing human milk to vulnerable infants.
Published on
CHOP pediatric oncology researchers have pinpointed a crucial change in a single DNA “letter” that predisposes children to an aggressive form of neuroblastoma.
Published on
The Children’s Hospital of Philadelphia’s (CHOP) Division of Orthopedics was recently named one of Becker’s Hospital Review’s 100 Hospitals with Great Orthopedic Programs for 2015.
Published on
CHOP researchers have taken a significant step forward in developing gene therapy against Batten disease, a fatal neurodegenerative disorder that strikes children.
Published on
The Children's Hospital of Philadelphia and Mount Sinai Health System have announced an alliance to make innovative treatments available to New York families.